Vivesto AB VIVE
Free
No email, no account, no signup.
General analysis — not personal advice.
Bull
Bear
Want to follow Vivesto AB? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Vivesto AB (formerly Oasmia Pharmaceutical) is a Swedish oncology-focused biotech developing cancer treatments for both humans and animals. The company leverages its XR-17 formulation platform and advances projects such as Paccal Vet and Cantrixil, while Apealea is partnered out. The company is loss-making and depends on financing and study readouts for value creation.
Exchange
Stockholm
Sector
Oncology drug development (human and veterinary)
Price & valuation
Last close
SEK 8.78
1 week
-2.0 %
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.